Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AMLPRNewsWire • 09/05/24
Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and TaiwanPRNewsWire • 09/03/24
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/06/24
Rigel Reports Second Quarter 2024 Financial Results and Provides Business UpdatePRNewsWire • 08/06/24
Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/30/24
Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business UpdatePRNewsWire • 07/30/24
Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow PotentialSeeking Alpha • 07/24/24
Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO® PatientsBusiness Wire • 06/27/24
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug ApplicationPRNewsWire • 06/24/24
Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual MeetingPRNewsWire • 06/03/24
Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid CongressPRNewsWire • 05/23/24
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/07/24
Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/30/24
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business UpdatePRNewsWire • 04/30/24